Dabigatran etexilate for nonvalvular atrial fibrillation in real practice and promises for its use to prevent stroke

Dabigatran etexilate for nonvalvular atrial fibrillation in real practice and promises for its use to prevent stroke

The capabilities of antithrombotic therapy to prevent thromboembolic events in nonvalvular atrial fibrillation (AF) are substantially extended after designing and clinically introducing new oral anticoagulants, one of which is dabigatran. A wealth of world clinical experience with dabigatran has con...

Full description

Bibliographic Details
Main Author: A.V. Fonyakin
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2014-06-01
Series:Nevrologiâ, Nejropsihiatriâ, Psihosomatika
Subjects:
atrial fibrillation
stroke prevention
dabigatran
Online Access:https://nnp.ima-press.net/nnp/article/view/394
id doaj-0733da3cb95d4520b54adbd0a97e78ce
record_format Article
spelling doaj-0733da3cb95d4520b54adbd0a97e78ce2021-07-29T08:58:35ZrusIMA-PRESS LLCNevrologiâ, Nejropsihiatriâ, Psihosomatika2074-27112310-13422014-06-0162445010.14412/2074-2711-2014-2-44-50384Dabigatran etexilate for nonvalvular atrial fibrillation in real practice and promises for its use to prevent strokeA.V. Fonyakin0Neurology Research Center, Russian Academy of Medical Sciences, MoscowThe capabilities of antithrombotic therapy to prevent thromboembolic events in nonvalvular atrial fibrillation (AF) are substantially extended after designing and clinically introducing new oral anticoagulants, one of which is dabigatran. A wealth of world clinical experience with dabigatran has confirmed its efficacy and safety provided that all recommendations for dosage regimens are followed. The universal properties of the drug can hope that the indications for its use will be extended and will not be confined to the prevention and treatment of venous and atrial thromboses and thromboembolisms. Whether dabigatran may be used in acute myocardial infarction and coronary stenting in the presence of nonvalvular AF, left ventricular thrombosis, and cardiomyopathies is being considered today.https://nnp.ima-press.net/nnp/article/view/394atrial fibrillationstroke preventiondabigatran
collection DOAJ
language Russian
format Article
sources DOAJ
author A.V. Fonyakin
spellingShingle A.V. Fonyakin
Dabigatran etexilate for nonvalvular atrial fibrillation in real practice and promises for its use to prevent stroke
Nevrologiâ, Nejropsihiatriâ, Psihosomatika
atrial fibrillation
stroke prevention
dabigatran
author_facet A.V. Fonyakin
author_sort A.V. Fonyakin
title Dabigatran etexilate for nonvalvular atrial fibrillation in real practice and promises for its use to prevent stroke
title_short Dabigatran etexilate for nonvalvular atrial fibrillation in real practice and promises for its use to prevent stroke
title_full Dabigatran etexilate for nonvalvular atrial fibrillation in real practice and promises for its use to prevent stroke
title_fullStr Dabigatran etexilate for nonvalvular atrial fibrillation in real practice and promises for its use to prevent stroke
title_full_unstemmed Dabigatran etexilate for nonvalvular atrial fibrillation in real practice and promises for its use to prevent stroke
title_sort dabigatran etexilate for nonvalvular atrial fibrillation in real practice and promises for its use to prevent stroke
publisher IMA-PRESS LLC
series Nevrologiâ, Nejropsihiatriâ, Psihosomatika
issn 2074-2711
2310-1342
publishDate 2014-06-01
description The capabilities of antithrombotic therapy to prevent thromboembolic events in nonvalvular atrial fibrillation (AF) are substantially extended after designing and clinically introducing new oral anticoagulants, one of which is dabigatran. A wealth of world clinical experience with dabigatran has confirmed its efficacy and safety provided that all recommendations for dosage regimens are followed. The universal properties of the drug can hope that the indications for its use will be extended and will not be confined to the prevention and treatment of venous and atrial thromboses and thromboembolisms. Whether dabigatran may be used in acute myocardial infarction and coronary stenting in the presence of nonvalvular AF, left ventricular thrombosis, and cardiomyopathies is being considered today.
topic atrial fibrillation
stroke prevention
dabigatran
url https://nnp.ima-press.net/nnp/article/view/394
work_keys_str_mv AT avfonyakin dabigatranetexilatefornonvalvularatrialfibrillationinrealpracticeandpromisesforitsusetopreventstroke
_version_ 1721250668543475712

Similar Items